Table 2.
Antiproliferative Assay in HL-60 Cellsa
| compd | GI50 (95% CI) μM | TGI (95% CI) μM | LC50 (95% CI) μM |
|---|---|---|---|
| 1 | 0.52(0.19–1.42) | 1.36(0.65–2.85) | 1.88(0.72–4.90) |
| 2 | 0.84 (0.19–3.79) | 3.99(1.03–15.4) | 10.1 (0.78–130) |
| 3 | 1.13(0.64–20.1) | 12.2(1.98–75.7) | nd |
| 4 | 16.9(4.68–61.3) | nd | nd |
| 5 | 1.69(0.46–6.20) | 7.29(1.64–32.5) | 21.3(0.33–1400) |
| 6 | 1.77(0.52–6.05) | 5.70 (2.24–14.5) | 8.07(2.70–24.1) |
| 7 | 0.69 (0.07–7.12) | 5.58(1.18–27.3) | 17.7(0.45–700) |
| 8 | 1.00(0.57–1.75) | 2.14(1.10–4.15) | 3.11 (1.19–8.15) |
| 9 | 0.75(0.41–1.40) | 1.74(0.97–3.12) | 2.54(1.13–5.70) |
| 10 | 0.58(0.33–1.01) | 1.18(0.68–2.03) | 1.66(0.76–3.62) |
| 11 | 24.7(11.9–51.1) | 46.2(31.3–68.1) | nd |
| 12 | 8.32 (4.21–16.5) | 18.3(8.17–41.1) | 23.8(9.17–61.7) |
a
Antiproliferative assays were conducted in the HL-60 (human promyelocytic leukemia) cell line. nd is not determined.